TY - JOUR
T1 - Predictors of mefloquine treatment failure: A prospectivestudy of 1590 patients with uncomplicated falciparum malaria: A prospectivestudy of 1590 patients with uncomplicated falciparum malaria
AU - Ter Kuile, Feiko
AU - Luxemburger, Christine
AU - Nosten, FranÇois
AU - Thwai, Kyaw Lay
AU - Chongsuphajaisiddhi, Tan
AU - White, Nicholas J.
PY - 1995/11/1
Y1 - 1995/11/1
N2 - The factors which identify patients at risk of treatment failure were characterized in 1590 children and adults with uncomplicated falciparum malaria treated with 15 or 25 mg/kg of mefloquine on the borders of Thailand. Six independent predictors of failure were identified using multiplelogistic regression. Age ≤2 years (odds ratio [OR] 4.54), 3-15 years (OR 4.4), vomiting <30 min after a single dose of 25 mg/kg (despite re-administration of the dose) (OR 2.5) and diarrhoea after treatment (OR 3.6) were the strongest predictors of failure by day 7. Parasitaemias >10 000/mm3 (OR 1.4), and fever with a history of recent vomiting (OR 1.6) were risk factors for recrudescence of the infection between days 10 and 28. Patients treated with mefloquine in the previous 2 months were also at increased risk of failure (OR 2.38), particularly if they were anaemic (haematocrit <30%) (OR 5.96), which suggested that they had recrudescentinfections at presentation. Combined, these 6 factors identified half of all treatment failures. Vomitingand diarrhoea accounted for 24% of the early failures in children. Patients at increased riskof treatment failure should be monitored closely and given early alternative treatment if fever andparasites persist for ≥3 d.
AB - The factors which identify patients at risk of treatment failure were characterized in 1590 children and adults with uncomplicated falciparum malaria treated with 15 or 25 mg/kg of mefloquine on the borders of Thailand. Six independent predictors of failure were identified using multiplelogistic regression. Age ≤2 years (odds ratio [OR] 4.54), 3-15 years (OR 4.4), vomiting <30 min after a single dose of 25 mg/kg (despite re-administration of the dose) (OR 2.5) and diarrhoea after treatment (OR 3.6) were the strongest predictors of failure by day 7. Parasitaemias >10 000/mm3 (OR 1.4), and fever with a history of recent vomiting (OR 1.6) were risk factors for recrudescence of the infection between days 10 and 28. Patients treated with mefloquine in the previous 2 months were also at increased risk of failure (OR 2.38), particularly if they were anaemic (haematocrit <30%) (OR 5.96), which suggested that they had recrudescentinfections at presentation. Combined, these 6 factors identified half of all treatment failures. Vomitingand diarrhoea accounted for 24% of the early failures in children. Patients at increased riskof treatment failure should be monitored closely and given early alternative treatment if fever andparasites persist for ≥3 d.
KW - Malaria
KW - Mefloquine treatment failure
KW - Plasmodium falciparum
KW - Risk factors
U2 - 10.1016/0035-9203(95)90435-2
DO - 10.1016/0035-9203(95)90435-2
M3 - Article
SN - 0035-9203
VL - 89
SP - 660
EP - 664
JO - Transactions of the Royal Society of Tropical Medicine and Hygiene
JF - Transactions of the Royal Society of Tropical Medicine and Hygiene
IS - 6
ER -